LYTIR

Insider · SEC Form 4 · Director, 10% Owner

Fairmount Funds Management LLC

In the 12 months to Nov 19, 2026, on the open market: bought $12.4M of CBIO; sold $699.7M of SYRE, ORKA. Filed a median of 0 business days after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

Insider purchases and sales, by month (last 12 months)Insider purchases: $12.4M in total; Insider sales: $699.7M in total.Jun: Insider sales $399.7MJul: Insider purchases $12.4MJul: Insider sales $300.0MDecJanFebMarAprMayJunJulAugSepOctNov$12.4M$399.7M
Insider purchases above the line: $12.4MInsider sales below: $699.7M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
  1. CBIOBought: CRESCENT BIOPHARMA, INC. Jul 16, 2026 853,450 shares filed Jul 20, 2026 3,601,316 shares held indirectly after, as filed filing $12.4M
  2. ORKASold: Oruka Therapeutics, Inc. Jul 1, 2026 3,553,410 shares filed Jul 1, 2026 1,131,954 shares held indirectly after, as filed filing $300.0M
  3. SYRESold: Spyre Therapeutics, Inc. Jun 23, 2026 4,684,781 shares filed Jun 23, 2026 0 shares held indirectly after, as filed filing $399.7M

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Stakes filed (13D/13G)

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Filings made under this filer's SEC CIK in the same 12 months, newest first; the figure is the percentage the filing states. Every recent 13D and 13G

  1. INMFairmount Funds Management LLC filed Nov 12, 2026 Schedule 13D may seek influence 10,555,507 shares issuer: Mentari Therapeutics, Inc. filing 19.99%
  2. TCRTFairmount Funds Management LLC filed Oct 15, 2026 Schedule 13D may seek influence 858,789 shares issuer: Alaunos Therapeutics, Inc. filing 19.99%
  3. SYREFairmount Funds Management LLC filed Oct 9, 2026 Schedule 13D/A may seek influence 10,185,961 shares issuer: SPYRE THERAPEUTICS, INC. filing 9.99%
  4. CYCNFairmount Funds Management LLC filed Sep 11, 2026 Schedule 13D may seek influence 9,103,729 shares issuer: Korsana Biosciences, Inc. filing 19.99%
  5. APGEFairmount Funds Management LLC filed Sep 3, 2026 Schedule 13D/A may seek influence 0 shares issuer: Apogee Therapeutics, Inc. filing 0%
  6. CBIOFairmount Funds Management LLC filed Jul 20, 2026 Schedule 13D/A may seek influence 6,593,385 shares issuer: CRESCENT BIOPHARMA, INC. filing 16.5%
  7. ORKAFairmount Funds Management LLC filed Jul 1, 2026 Schedule 13D/A may seek influence 14,553,895 shares issuer: Oruka Therapeutics, Inc. filing 19.47%
  8. APGEFairmount Funds Management LLC filed Jun 23, 2026 Schedule 13D/A may seek influence 6,713,519 shares issuer: Apogee Therapeutics, Inc. filing 9.84%
  9. SYREFairmount Funds Management LLC filed Jun 23, 2026 Schedule 13D/A may seek influence 8,835,440 shares issuer: Spyre Therapeutics, Inc. filing 9.15%

Other Form 4 entries

Not counted above: entries this filer reported on Form 4 in the same 12 months that are not open-market purchases or sales. Each entry is one line of a filing.

  • APGE: disposed of to the company (code D), 3 entries, Sep 3, 2026
  • APGE: option exercise or conversion (code M), 2 entries, Aug 7, 2026
  • ORKA: conversion (code C), 1 entry, Jul 1, 2026
  • SYRE: conversion (code C), 1 entry, Jun 23, 2026
Code C
A conversion of a derivative security, such as preferred stock or units, into shares.
Code D
Shares disposed of to the company itself, such as shares the company took back.
Code M
An exercise or conversion of a derivative security received from the company, such as stock options.

Source: the same SEC Form 4 filings. The codes are the SEC's own transaction codes; the meanings above are a plain-words reading of the SEC's Form 4 instructions.